The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis.

ABSTRACT:

Introduction

The therapy of rheumatoid arthritis (RA) was advanced by biological agents, yet costly. This study aims to identify the effective threshold dose of etanercept (ENT) and cost-effectiveness in methotrexate (MTX)-resistant RA in real world.

Methods

Eligible patients had an inadequate response (DAS28-ESR > 3.2) to initial MTX monotherapy, and subsequently received etanercept. The effective cut-off value of cumulative dose was identified to maintain remission response (DAS28-ESR < 2.6) at month 24 by using restricted cubic splines. Remission rate, low disease activity (LDA) rate, glucocorticoid exposure, safety, and cost-effectiveness were compared between the saturated and non-saturated dose groups divided by the cut-off dose.

Results

Seventy-eight (14.2%) of

SUBMITTER: Chen F 

PROVIDER: S-EPMC10497429 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature